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http://www.biomedcentral.com/1471-2490/14/39CASE REPORT Open AccessPrimary mucin-producing urothelial-type
adenocarcinoma of the prostatic urethra diagnosed
on TURP: a case report and review of literature
Elisabeth M Sebesta1*, Hossein S Mirheydar2,3, J Kellogg Parsons2,3, Jessica Wang-Rodriguez3 and A Karim Kader2,3Abstract
Background: Mucin-producing urothelial-type adenocarcinoma of the prostatic urethra is extremely rare. These
lesions must be differentiated from other mucinous tumors including mucin-producing prostatic adenocarcinoma
and metastases from either colonic or bladder primaries.
Case presentation: We report here a case of urothelial-type adenocarcinoma arising from the prostatic urethra.
The patient is an 81 year-old man with a history of pT1 urothelial cell carcinoma of the bladder status post trans-urethral
resection of bladder tumor (TURBT) who initially presented with irritative lower urinary tract symptoms and mucosuria
refractory to Flomax and finasteride. A shared decision was made for the patient to undergo trans-urethral resection of
prostate (TURP). At the time of surgery, a papillary tumor emanating from the prostatic urethra was found and no
urothelial lesions were noted in the bladder. Pathology of the resected prostatic chips revealed an invasive
adenocarcinoma with intestinal-type differentiation that stained positive for CK7, CK20, and villin, but negative for
PSA, PSAP, uroplakin, and CDX-2. Colonoscopy was normal and CT scan did not show any evidence of colonic
lesions nor visceral or lymph node metastases. Thus, the patient was diagnosed with a primary urothelial-type
adenocarcinoma of the prostatic urethra.
Conclusion: Herein we review the literature regarding this unusual entity, and discuss the differential diagnosis,
immunohistochemistry, and the importance of correctly identifying this rare tumor.
Keywords: Mucin-producing adenocarcinoma, Prostatic urethra, Trans-urethral resection of prostate, Urothelial-type
adenocarcinoma, AdenocarcinomaBackground
The most common mucin-producing adenocarcinoma of
the prostate gland is a primary prostatic adenocarcinoma
with mucin production [1]. The differential diagnosis in-
cludes secondary prostatic lesions of primary colonic or
bladder origin and urothelial-type adenocarcinoma arising
directly from the prostatic urethra or prostatic ducts. The
latter diagnosis is exceedingly rare, with only 18 cases
identified in the literature to date [1-4]. Urothelial-type
adenocarcinoma of the prostatic urethra is histologically
identical to nonurachal adenocarcinoma of the bladder,
however it arises from urethritis glandularis or glandu-
lar metaplasia of the prostatic urethra [1,5]. We describe* Correspondence: ems2230@columbia.edu
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unless otherwise stated.a case of primary urothelial-type adenocarcinoma of the
prostatic urethra that was initially diagnosed on TURP
specimen, with a discussion of its clinical-pathological
correlation.
Case presentation
An 81 year-old Caucasian man with past medical history
of COPD, on home oxygen, presented with mucosuria,
urinary frequency, and nocturia. Digital rectal exam dem-
onstrated a 60 cc benign-feeling gland and the patient’s
PSA was 0.38. The patient has a history of a 2.5 cm pT1
urothelial cell carcinoma at the bladder dome status post
TURBT 19 months prior (Figure 1a, 1b). The patient
had two subsequent urine cytology examinations 5 and
2 months prior, both of which were negative for malignant
cells. The patient recently noticed mucosuria. His subsequent
surveillance cystoscopy demonstrated a normal-appearingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
(a) 
(b) 
Figure 1 pT1 urothelial cell carcinoma. Patient’s original biopsy showing high grade papillary urothelial carcinoma of the bladder.
Hematoxylin-eosin stain. (a) 40x magnification. (b) 100× magnification.
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tatic urethra and median lobe of the prostate, however no
distinct urothelial mass was seen and the bladder urothe-
lium appeared unremarkable. There was evidence of a pros-
tatic adenoma, and the patient was scheduled for TURP
via greenlight PVP. During the procedure the prostatic ur-
ethra was clearly visualized. The prostatic adenoma seen
at the bladder neck was vaporized until the veromonta-
num was visualized. A white fibrinous material originating
from the veromontanum was seen. A prostatic resection
was initiated using bipolar TURP. Deep to the fibrinous
material, a papillary tumor was visualized. TURP was
completed using bipolar without incidence.
Pathological results
Final pathology revealed intestinal type epithelium in a
background of necrosis and inflammatory debris to-
gether with invasive adenocarcinoma with extensive in-
testinal differentiation (Figure 2a-d). The specimens were
found to stain strongly positive for CK20, CK7, and villin
(Figure 3a-c). Beta-catenin showed strong cytoplasmic and
membranous staining (Figure 3d). In addition, the tumors
were negative for uroplakin, CDX-2, PSA (Figure 4), and
PSAP staining. Final urine cytology contained atypical
urothelial cells suspicious for malignancy.
Follow-up
Due to the histological appearance of the prostatic tumor,
the patient underwent a colonoscopy to rule out a primarycolonic malignancy. Multiple diverticula were found in
the sigmoid colon and six sessile polyps were biopsied
from the ascending and descending colon, all of which
were found to be benign. In addition the patient under-
went a CT urogram, which was without evidence of a fill-
ing defect or bladder primary. The patient was thus given
the diagnosis of primary adenocarcinoma of the prostatic
urethra. He was evaluated for radical cystectomy and was
deemed very high risk for operative management due to
his severe chronic pulmonary obstructive disease (COPD).
He underwent an oncology evaluation including PET CT
scan demonstrating no evidence of metastatic disease.
Based on this evaluation, the patient declined to undergo
exenterative surgery due to concerns for decreased quality
of life. A decision was thus made for him to undergo local
aggressive trans-urethral resection with adjuvant multi-
modal therapy including 42 days of Intensity Modulated
Radiotherapy (IMRT) and radiosensitizing oral capecita-
bine chemotherapy (900 mg po qd × 6 weeks). Capeitabine
versus a platinum-based chemotherapy was chosen as the
patient had several contraindications to platihum-based
chemotherapy including hearing loss, CKD, and peripheral
neuropathy. His PSA remains low at 0.074.
Discussion
Mucin-producing urothelial-type adenocarcinoma of the
prostate is an exceedingly rare diagnosis, and one that is
poorly understood thus far. It is thought to arise from
precursor lesions (urethritis glandularis and glandular
(a) (b) 
(d) (c) 
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Figure 2 TURP prostate chip specimen. Hematoxylin-eosin stain. (a) 10× magnification, arrow demonstrates adenocarcinoma of the prostate
with complex glandular arrangement. (b) 40× magnification, adenocarcinoma (*) at the edge of the TURP fragments which contrasts with nearby
benign prostatic glands (**). (c) 400× magnification, demonstrating extensive intestinal differentiation. (d) 40× magnification, adenocarcinoma
with extensive mucin (M) dissecting into the prostatic stroma.
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ducts [1,5]. The published case reports of this disease have
helped to determine some of the clinical and pathological
features.
In 1996, Tran and Epstein reported the first two cases
of mucinous adenocarcinoma arising from the prostatic
urethra. In both cases, the patient presented with ob-
structive urinary symptoms. The gross pathology of the
tumors revealed mucin lakes lined by tall columnar epi-
thelium, one specimen of which contained mucin-positive
signet ring cells. Both patients had a negative colonoscopy
and cystoscopy to rule out bladder and colon primaries,
and both had low PSA values. The patients remained
without evidence of disease with short-term follow-up fol-
lowing radical retropubic prostatectomy in the first patient
and external beam radiotherapy in the second [2].
Curtis, et al. in 2005 described an additional two cases.
One man presented with urinary retention, bilateral flank
pain, microhematuria, and renal insufficiency and the
other with a nodule on digital rectal exam. Again the pa-
tients had a low PSA and a negative cystoscopy and colon-
oscopy work-up. The first patient underwent TURP for
bladder outlet obstruction, and shortly after was found
have liver metastases and died from disseminated intra-
vascular coagulation. The second patient was treated withradical prostatectomy with bilateral lymph node dis-
sections, and remained with no evidence of disease for
16 months of follow-up [3].
Osunkoya, et al. in 2007 published 15 cases identified
between 1990 and 2006, the largest collection to date.
All patients presented with an element of urinary ob-
structive symptoms, however other symptoms included
mucosuria (20%), hematuria (13.3%), and urinary tract
caliculi (20%). The PSA remained <1.5 in 9/10 patients
throughout follow-up. Treatment included TURP in 7/15
and radical pelvic resection in 8/15, including 5 radical
prostatectomies (3 of which underwent adjuvant therapy),
2 cystoprostatecomies, and 1 pelvic exenteration. Among
these men, 53% died of their disease at an average of
49.2 months from presentation, and all 8 men undergoing
radical resection had evidence of extraprostatic extension,
4 of whom developed metastatic disease to the lungs, liver,
pelvic side wall, and/or testes. The two men initially de-
scribed by Tran and Epstein as having no evidence of
disease at short-term follow-up both eventually died of
their disease at 13 and 63 months [4].
This large collection of cases encompassed only 0.02%
of their consult service for prostate cancer. In addition,
this description of cases was the first to truly highlight
the aggressiveness of the disease with a clinical course
(a) (b) 
(d) (c) 
Figure 3 Surgical specimen and positive pathological staining. (a) Diffusely positive staining for CK20. (b) Diffusely positive staining for CK7.
(c) Diffusely positive staining for villin. (d) Mostly cytoplasmic positive staining for beta-catenin.
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of the prostate. In these cases, bone metastases were not
present at time of progression, and progression of disease
to death was more common and rapid [4].
All case reports thus far have helped to identify the
histologic features and the immunohistochemical staining
that can help differentiate this disease on pathology. Pre-
cursor lesions identified in men include glandular meta-
plasia of the prostatic urethra (53%) and villous featuresFigure 4 Surgical specimen and negative pathological staining.
Diffusely negative staining for PSA.(47%). All specimens contained mucin pools lined by pseu-
dostratified columnar mucinous epithelium with varying
degrees of cytologic atypia. Other less commonly demon-
strated patterns include necrosis, signet ring cells, and
perineural invasion [1-4].
Curtis, et al. identified that in comparison to prostatic
adenocarcinoma with mucin production, both urothelial-
type adenocarcinoma arising in the prostatic urethra and
secondary adenocarcinoma of colonic origin involving the
prostate were PSA and PSAP negative and CK20 positive.
In addition they proposed that a colonic primary would
stain negative for CK7 and 34βE12 (high molecular weight
cytokeratin) while a prostatic primary would stain positive
[3]. Osunkoya, et al. corroborated these findings, in addition
to identifying that 10/15 specimens in their study also
stained negative for beta-catenin and CDX-2 [4]. Tamboli,
et al. demonstrated that villin staining was useful in differ-
entiating the primary tumor, as it was positive in colonic
adenocarcinoma but negative in urothelial carcinoma with
glandular differentiation [6]. However villin is also positive
in primary enteric-type adenocarcinoma of the urinary
tract, and therefore not helpful in distinguishing this diag-
nosis from colonic metastases.
Conclusion
Using the work of our predecessors, we were able to diag-
nose the case reported here with primary mucin-producing
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We obtained an immunohistochemical profile including
PSA, PSAP, CK7, CK20, CDX-2, and villin. This in addition
to a negative colonoscopy and CT urogram helped to dif-
ferentiate between prostatic adenocarcinoma with mucin
production from secondary lesions from colon or bladder
to suggest a diagnosis of primary urothelial-type adenocar-
cinoma of the prostatic urethra. As evidenced by previous
case reports, making the correct diagnosis in this disease
early is crucial. First, it may save the patient multiple inva-
sive procedures and work-up to exclude other primaries.
In addition, the distinction from prostatic adenocarcinoma
with mucin production is critical, as the disease described
here is more aggressive and deadly. It cannot be treated
with hormonal therapy and assigning a Gleason score is
rendered useless. Continuing to gather data and case re-
ports will be crucial to help determine the clinical behav-
ior and to identify the optimal treatment for this rare and
aggressive disease.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for review
by the Series Editor of this journal.
Abbreviations
TURP: Trans-urethral resection of prostate; TURBT: Trans-urethral resection of
bladder tumor; PSA: Prostate-specific antigen; PSAP: Prostatic-specific acid
phosphatase; CK7: Cytokeratin 7; CK20: Cytokeratin 20; CDX-2: Caudal type
homeobox 2.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EMS wrote the manuscript and made the revisions. JWR performed the
pathological evaluation and provided the slides for pathology. HAM, JKP, and
AKK treated the patient. HAM obtained written informed consent from the
patient for submission of this case report. All authors read and approved the
final manuscript.
Author details
1Columbia University College of Physicians and Surgeons, 630 W. 168th St,
New York, NY 10032, USA. 2UC San Diego Health System, 200 W. Arbor Drive
#8897, San Diego, CA 92103-8897, USA. 3VA San Diego Healthcare System,
3350 La Jolla Village Dr. (113), San Diego, CA 92161, USA.
Received: 2 January 2014 Accepted: 17 April 2014
Published: 22 May 2014
References
1. Bohman KD, Osunkoya AO: Mucin-producing tumors and tumor-like
lesions involving the prostate: a comprehensive review. Adv Anat Pathol
2012, 19:374–387.
2. Tran KP, Epstein JI: Mucinous adenocarcinoma of urinary bladder type
arising from the prostatic urethra. Distinction from mucinous
adenocarcinoma of the prostate. Am J Surg Pathol 1996, 20:1346–1350.
3. Curtis MW, Evans AJ, Srigley JR: Mucin-producing urothelial-type
adenocarcinoma of the prostate: report of two cases of a rare and
diagnostically challenging entity. Mod Pathol 2005, 18:585–590.4. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type
adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol 2007,
31:1323–1329.
5. Uchijima Y, Ito H, Takahashi M, Yamashina M: Prostate mucinous
adenocarcinoma with signet ring cell. Urology 1990, 36:267–268.
6. Tamboli P, Mohsin SK, Hailemariam S, Amin MB: Colonic adenocarcinoma
metastatic to the urinary tract versus primary tumors of the urinary tract
with glandular differentiation: a report of 7 cases and investigation
using a limited immunohistochemical panel. Arch Pathol Lab Med 2002,
126:1057–1063.
doi:10.1186/1471-2490-14-39
Cite this article as: Sebesta et al.: Primary mucin-producing urothelial-
type adenocarcinoma of the prostatic urethra diagnosed on TURP: a case
report and review of literature. BMC Urology 2014 14:39.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
